Dihydroberberine

Dihydroberberine is a naturally occurring isoquinoline alkaloid with anti-inflammatory, anti-atherosclerotic, hypolipidemic and anti-tumor activities. Dihydroberberine inhibits the human ether-related gene (hERG) channel and significantly reduces the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine also blocks the TLR4/MyD88/NF-κB signaling pathway to reduce pro-inflammatory cytokines and immunoglobulins, and has inhibitory effects on DSS (HY-116282C) -induced experimental colitis. Dihydroberberine also increases the sensitivity of lung cancer to sunitinib (HY-10255A), with synergistic efficacy[1][2].

Product Specifications

CAS Number

[483-15-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HSP; Potassium Channel

Type

Natural Products

Related Pathways

Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Cancer; Inflammation/Immunology; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/dihydroberberine.html

Purity

99.30

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 70°C)

Smiles

COC1=CC=C(C=C23)C(CN2CCC(C3=C4)=CC5=C4OCO5)=C1OC

Molecular Formula

C20H19NO4

Molecular Weight

337.37

Precautions

H302, H315, H319, H335

References & Citations

[1]Yu D, et al. Inhibitory effects and mechanism of dihydroberberine on hERG channels expressed in HEK293 cells. PLoS One. 2017 Aug 1;12 (8) :e0181823.|[2]Li C, et al. Dihydroberberine, an isoquinoline alkaloid, exhibits protective effect against dextran sulfate sodium-induced ulcerative colitis in mice. Phytomedicine. 2021 Sep;90:153631.